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Influenza A virusa b s t r a c t
Driven by the concept of plug-and-play cell culture-based viral vaccine production using disposable
bioreactors, we evaluated an orbital shaken bioreactor (OSB) for human influenza A virus production
at high cell concentration. Therefore, the OSB model SB10-X was coupled to two hollow fiber-based per-
fusion systems, namely, tangential flow filtration (TFF) and alternating tangential flow filtration (ATF).
The AGE1.CR.pIX avian suspension cells grew to 50  106 cells/mL in chemically defined medium, main-
taining high cell viabilities with an average specific growth rate of 0.020 h1 (doubling time = 32 h).
Maximum virus titers in the range of 3.28–3.73 log10(HA units/100 mL) were achieved, corresponding
to cell-specific virus yields of 1000–3500 virions/cell and productivities of 0.5–2.2  1012 virions/L/d.
This clearly demonstrates the potential of OSB operation in perfusion mode, as results achieved in a refer-
ence OSB batch cultivation were 2.64 log10(HA units/100 mL), 1286 virions/cell and 1.4 1012 virions/L/d,
respectively. In summary, the SB10-X bioreactor can be operated with ATF and TFF systems, which is
to our knowledge the first report regarding OSB operation in perfusion mode. Moreover, the results
showed that the system is a promising cultivation system for influenza A virus vaccine production.
The OSB disposable bioreactor has the potential for simplifying the scale-up from shake flasks to the
large-scale bioreactor, facilitating rapid responses in the event of epidemics or pandemics.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Production processes in the pharmaceutical industry are con-
stantly being improved to become faster, safer, more efficient
and flexible, as new technologies become available [1]. Perfusion
processes have been used since the 900s for large-scale manufac-
turing of labile biopharmaceuticals that show fast degradation in
conventional batch cultures. Nowadays, this operational mode is
also used for production of a broader class of molecules including
stable products (i.e., monoclonal antibodies) [2]. In perfusion,
higher volumetric productivities can be achieved and product
quality is often improved compared to other modes of operation
[3]. In the field of virus vaccine manufacturing, a future scenario
might be the establishment of high cell density perfusion processes
for high titer virus production. Promising perfusion studies havebeen performed at lab-scale for virus vaccine production, but such
processes are not yet reported for commercial vaccines. The imple-
mentation of process changes in biologics manufacturing requires
time and involves significant costs. Therefore, even simple static
systems are employed today for large-scale processes, which use
adherent cells for virus propagation, including roller bottles and
multilayer cultivation systems. The use of controlled bioreactor
systems such as packed-bed bioreactors or stirred tank bioreactors
(STRs) with microcarriers is also reported [4].
Following the trend towards process intensification, efforts
have been made to develop designer cells for viral vaccine pro-
duction that grow in chemically defined medium and in suspen-
sion, which facilitates perfusion operation. This includes, for
example, AGE1.CR, AGE1.CR.pIX, CAP, EB66 and PER.C6 cells [5].
Concerning cell culture processes in general, shake flasks (Erlen-
meyer) and centrifuge tubes with vented caps are widely used
for screening of clones or optimization of process conditions at












Fig. 1. Set-up used for the perfusion cultivations in the orbital shaken bioreactor
(OSB). Two approaches were evaluated: either an alternating tangential flow
filtration (ATF) system was coupled to the bottom of the OSB or a tangential flow
filtration (TFF) unit was connected using lower and upper ports plus a centrifugal
pump with magnetic levitation for recirculation. The arrows indicate the flow
direction in the recirculation loop. A peristaltic pump was used for feeding and an
additional pumpwas connected to the hollow fiber modules of ATF and TFF systems
for harvesting.
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processes that are not easily transferred to STR. Cell growth can
be limited or even impaired in STR depending on the sensitivity
of cell lines to shear stress originating from stirring and bubble
aeration [8]. Orbital shaken bioreactors (OSB) are a valuable alter-
native to STRs, as the transfer from shake flasks to OSB is simpli-
fied because these systems rely on the same basic principles for
mixing and aeration and, therefore, similar hydrodynamic param-
eters. For this reason, scale-up in OSB can be easier, when vessels
with similar geometries are used. This concerns, in particular, the
adjustment of operational parameters such as shaking frequency,
shaking orbit and filling volume to meet scale-up criteria (e.g.
providing sufficient oxygen transfer capacity) [6,9]. In the last
15 years, many studies using orbital shaken technology were car-
ried out using different bioreactor vessels: cylindrical, square-
shaped and helical [10]. Surface aeration is an important charac-
teristic of OSB, which results in low shear stress and reduced
foam formation. For the cylindrical orbital shaken bioreactors,
high volumetric oxygen transfer rates and short mixing times
can be achieved depending on the bioreactor size and the shaking
frequency [6,11].
Moreover, the development of single-use bioreactors rapidly
increased after the first Wave bioreactor was introduced [12].
The main advantages of using single-use technology for cell culture
are reduced validation and operating costs and faster turnaround
between batches (no need for clean in place and steam in place
procedures), besides flexibility for multiproduct facilities [13].
Examples of disposable bioreactors are: STR systems Xcellerex
XDR (GE Healthcare) and S.U.B. (Thermo Scientific Hyclone), up
to 2000 L in both cases; Wave bioreactors (GE Healthcare) up to
1000 L and wave-mixed bioreactors BIOSTAT B RM (rocking
motion) (Sartorius-Stedim) up to 200 L, both with maximumwork-
ing volume (wv) equal to half of the total volume; and orbital sha-
ken benchtop bioreactors (Adolf Kühner AG), up to 2500 L (wv).
Wave systems are mainly used as seed-train bioreactors [14], but
not so much for production compared to disposable STRs [15].
The STRs, however, involve a higher complexity regarding mount-
ing the reactors with the integrated stirrer, while OSB enable an
easier operation for large-scale bioreactors, as moving parts for
stirring are not required. The latter can also contribute to lower
running costs. Despite the simplicity of operation and the potential
for an easier scale-up provided by OSB, studies were limited to
batch and fed-batch operation [6]. To our knowledge, reports of
OSB in perfusion mode are not available. Meanwhile, very high cell
concentrations (108 cells/mL) were reached in Wave bioreactors
[16], exemplifying a successful perfusion operation in a system
with surface aeration.
As indicated above, virus vaccine production in lab-scale perfu-
sion bioreactors has shown increased productivities using suspen-
sion cells in STR [17–20] and other cultivations systems, e.g.
hollow fiber bioreactors [21]. In the present study, a lab-scale
single-use OSB (SB10-X) was evaluated for influenza A virus
(IAV) production, combining the orbital shaken technology with
perfusion. As cell substrate we used the AGE1.CR.pIX suspension
cell line, which grows in chemically defined medium to high cell
concentration and has been previously characterized for virus
propagation [18,22,23]. Here, we investigated the feasibility of
OSB operation mode using either tangential flow filtration (TFF)
or alternating tangential flow filtration (ATF) perfusion devices.
Furthermore, IAV replication dynamics was assessed by flow
cytometry, demonstrating that the cell population was sucessfully
infected. Overall, we show efficient IAV production with cell-
specific virus yields up to 3500 virions/cell. This represents an
increase of about 2-fold compared to previous data from our lab
using the same virus strain and AGE1.CR cells.2. Material and methods
2.1. Cell line
Avian AGE1.CR.pIX suspension cells (ProBioGen AG) were culti-
vated in chemically-defined CD-U3 medium (Biochrom-Merck)
supplemented with 2 mM L-glutamine, 2 mM alanine and 10 ng/L
LONG R3 IGF-I (Sigma). Cells were grown in baffled shake flasks
at 185 rpm, 37 C, and 5% CO2. For passaging, cells were seeded
at 0.8  106 cells/mL (viable cell concentration, Xv) every 3 to
4 days using 125 mL flasks (VWR, # 89095-262) with 50 mL wv.
Cells were routinely subcultured until passage 100. For propaga-
tion of the inoculum, 1 L flasks (Thermo Scientific, # 4116-1000)
with maximum 600 mL wv were incubated at 150 rpm. For some
bioreactor cultivations, two flasks were used for inoculation.
2.2. Cultivations in the orbital shaken bioreactor
The SB10-X OSB (Adolf Kühner AG) with 12 L single-use stan-
dard bags was used for cultivations of AGE1.CR.pIX cells. Inocula-
tion was done at 1.0–1.2  106 cells/mL (Xv) with 5 L initial wv.
The cultivations were carried out at 37 C with an initial shaking
frequency of 70 rpm (5 cm shaking diameter). Dissolved oxygen
(DO) and pH were controlled manually through adjustment of
the gas composition in the output flow. Gassing flow rates (air,
O2 and CO2) were 300–500 mL/min. The percentage of oxygen
(O2) in the gas mixture was set to 25–50% over the course of the
cell growth phase to maintain the DO above 80%. The percentage
of CO2 in the gas mixture was adjusted to 0–5% during the cell
growth phase for pH values above 7.2. Process parameters in refer-
ence cultivations performed in shake flasks were described by
Vázquez-Ramírez et al. [18]. For virus production (Section 2.3),
the percentage of O2 in the gas mixture was increased to 40–60%
and the shaking frequency was increased to 80–90 rpm.
For perfusion cultivations, either an ATF2 system with the
C24U-v2 controller (Repligen) or a TFF system with a low shear
centrifugal pump with magnetic levitation (Puralev 200MU,
Levitronix) was used (Fig. 1). For ATF operation, the hollow fiber
(HF; Repligen, F2:RF02PES) was coupled to the bioreactor via a port
J. Coronel et al. / Vaccine 37 (2019) 7011–7018 7013located in the bottom of the bag. For TFF operation, the HF (GE
Healthcare, UFP-500-E-4X2MA) was connected to the bag using a
bottom port (from the bioreactor to the lower inlet of the HF)
and an upper port (from the upper outlet of the HF to the bioreac-
tor). Perfusion was started approximately 2 days after inoculation
when the viable cell concentration was 3.5–5.0  106 cells/mL. Per-
fusion flow rates were adjusted by applying a cell-specific perfu-
sion rate of 0.06 nL/(cell  d) to support the glucose demand [18].
2.3. Infection conditions
Avian AGE1.CR.pIX cells were infected with human influenza
A/PR/8/34 H1N1 virus, derived from MCDK cells (Robert Koch
Institute, Amp. 3138, TCID50 = 1.23  108 virions/mL), with a
multiplicity of infection (MOI) of 103 or 105 infectious virions/
cell with addition of 107 U/cell of trypsin from a 5000 U/mL stock
solution prepared in PBS (Gibco, # 27250-018). To facilitate virus
uptake, perfusion was stopped for approximately 1 h after infec-
tion (by interrupting feeding and harvesting, while recirculation
was maintained) and was restarted thereafter. For virus produc-
tion, the bioreactor wv was increased from 5 L to 10 L (Table 1)
within 24 h post infection (hpi), following a hybrid fed-batch/
perfusion strategy [18,24]. In the present work, the perfusion mode
continued while the dilution step was performed, instead of
operating in fed-batch mode during a defined period of time and
afterwards in perfusion mode. Furthermore, a second dose of 107
U/cell trypsin was administered between 14 and 24 hpi to promote
multi-cycle replication, since the trypsin (26 kb) added at time of
infection might be washed out in the permeate over time.
2.4. Analytical assays for cells, metabolites and virus
Viable cell concentration and cell viability were measured using
a Vi-CELL XR (Beckman Coulter) and a validated protocol for
AGE1.CR.pIX cells with a maximum error (relative standard devia-
tion) of 5% [25]. Glucose, lactate, glutamine, and ammonium (NH4+)
concentrations were determined using a Bioprofile 100 Plus (Nova
Biomedical). Measurement of virus titer was done according to
standard procedures: total virus particles and infectious virus par-
ticles were measured with HA [26] and TCID50 assays, respectively
[27]. HA titers [log10(HA units/100 mL)] were converted into virus
concentration, Cvir [virions/mL] assuming binding of one virus par-
ticle per erythrocyte and a given erythrocyte concentration of
2  107 cells/mL (Eq. (1)) [28].
Cvir ¼ 2 107  10log10ðHAunits=100lLÞ ð1Þ2.5. Imaging flow cytometry: sampling, staining and data analysis
The fraction of infected and apoptotic cells was determined by
flow cytometry. Samples containing about 2  106 cells were col-
lected twice a day after infection and fixation was performed using
2% paraformaldehyde (Morphisto GmbH) during 30 min at 4 C.Table 1




ATF #1 5 105
ATF #2 7 103
TFF #1 8 103
TFF #2 8 103
a Bioreactor working volume in liters.
b Multiplicity of infection (MOI) in infectious virions per cell.Samples were centrifuged (10 min, 300g, 4 C) and the cell pellets
were resuspended in 1 mL of cold PBS. Subsequently, the cell sus-
pension was transferred to 15 mL falcon tubes containing 4.5 mL of
cold 70% ethanol (v/v) and samples were stored at 20 C until use.
Staining for viral nucleoprotein (NP) and DAPI were performed
similarly as described by Frensing et al. [29], but modifications in
the protocol were made to minimize antibody usage and cell loss
during washing steps. Blocking and antibody incubation steps
were performed in 25 mL wv. After incubation steps, cells were
washed two times. Subsequently, cells were resuspended in
30–50 mL FACS buffer and DAPI was added (approximately 5 mg/mL).
Acquisition was performed using an ImageStreamX Mark II Imag-
ing Flow Cytometer (Amnis, EMD Millipore); 10,000 events (single
cells) were collected. Data analysis was done using IDEAS software
(version 6.2). Infected cells were determined as positive for NP and
apoptotic cells by analyzing DAPI signal and brightfield images.
2.6. Calculations
The cell-specific virus yield (CSVY) and the culture medium pro-
ductivity (Pv ) were calculated from virus titers measured in the
bioreactor, whereas the virus in the permeate was not considered
since previous experiments demonstrated that virions do not pass
through the hollow fiber membranes [23]. CSVY [virions/cell] is the
ratio of the maximum virus concentration, Cvir,max [virions/mL],
and the maximum concentration of viable cells post infection,
Xv,max [cells/mL] (Eq. (2)). Because of the dilution step during virus
production phase, the bioreactor working volume, wv [L] at the
corresponding time points was considered, namely, t1 = t at Cvir,max
and t2 = t at Xv,max.
CSVY ¼ Cvir;max wv t1
Xv;max wv t2 ð2Þ
The culture medium productivity Pv [virions/L/d] takes into
account the maximum virus concentration, the respective working
volume, the total spent medium (Vtot) [L], and the total process
time (ttot) [d]considering cell growth and virus replication phases
(Eq. (3)).
Pv ¼ Cvir;max wv t1Vtot  ttot ð3Þ3. Results and discussion
3.1. Single-use bioreactor operation and bag design
Perfusion cultivations were carried out using standard bags
(Fig. 2-A) originally developed for batch and fed-batch processes.
Because some connections were not optimal for our application,
new perfusion bags were designed. The current version of the per-
fusion bag is shown in Fig. 2-B. Some important modifications
were: (1) reduction of the tube length for connection to the perfu-
sion systems to decrease the length of the recirculation loop; (2)
integration of a diptube to enable cell addition directly into the
medium, which is important for the TFF recirculation; (3) one addi-
tional perfusion connection in the bottom (two ports in total)
allowing for more flexibility regarding other process options. For
instance, two perfusion devices can be coupled to the OSB - one
used for the cell growth phase and the other for the virus produc-
tion phase. Another possibility is to use the second port as a back-
up, which can be relevant for industrial applications. The SB10-X
bioreactor system with the standard bag is shown in Fig. 2-C.
The connection of the HF with the OSB bag is done using the
bottom region of the bag (differently to the connection to a STR,
done via the bioreactor headspace using a dip tube). In the first
A B C 
Fig. 2. Schematic drawings of single-use bags employed for cell growth and virus production in the SB10-X orbital shaken bioreactor (Adolf Kühner AG, Switzerland): (A)
standard (# SMX76001) (B) perfusion (# SMX76003). Perfusion bags have two independent, short (12 cm) connections for perfusion devices in the bottom part and two
exhaust air filters (connected with a Y) in the upper part. (C) Photography of the standard bag inside the vessel module, placed on top of the shaking tray.
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mately 3 L), we observed air entry into the tubing connecting the
bioreactor and the ATF. Because the membrane material of the
HF requires operation in liquid phase and the presence of air
impairs its proper functioning, the minimum volume for perfusion
with ATF or TFF was increased to 5 L. Perfusion cultivations were
successfully carried out at constant 5 L wv and one example (ATF
#1) is shown in the results section. Aiming at a further increase
in wv during the virus production phase to improve the virus
yields [24], subsequent perfusion runs were carried out at 7 L
(ATF #2) or 8 L scale (TFF #1 and #2). Perfusion operation at 10 L
scale was also possible (not shown).
Before starting the processes, connections to the MPC couplings
of the bag were done under a biological safety cabinet. To enable
additional connections outside the cabinet, we used STT quick con-
nect couplings (Sartorius Stedim) in the tubing lines (e.g., feed and
inoculation), which were previously sterilized. Subsequently,
about 4 L of medium was added after the bag was inflated with
air (approximately 20 L of total volume). Following the time
required for equilibration and subsequent calibration of the DO
and pH sensors, cells and fresh medium were added to achieve
the initial 5 L wv.
In the subsequent experiments, cell growth in perfusion mode
was successfully carried out but an insufficient process control
after infection led to low virus yields (below 1000 virions/cell).
Typically after trypsin addition at TOI, an increased oxygen
demand was observed for a short time (1–2 hpi), regardless of
the cell line, medium and bioreactor system used. Although oxygen
control via bubbling did not indicate any oxygen limitation in pre-
vious experiments, headspace aeration and current control of the
SB10-X was not capable of a fast reactivity to cope with oxygen
demand of cells and, in some cases, a DO drop was observed soon
after infection. Therefore, the output gas mix was enriched with O2
by manually increasing its percentage before infection. Using this
configuration, virus production was enhanced (Section 3.3). After
the present study was carried out, the bioreactor controller was
updated regarding its response time to prevent oxygen limitation
in the beginning of the virus production phase.3.2. High cell concentration cultivations
The first cultivations were carried out to evaluate operational
conditions of the newly established perfusion set-ups using ATF
or TFF systems and to gain know-how regarding process control
for IAV production, as discussed in the previous section. After
adjusting initial parameters of each set-up, seven perfusion culti-
vations were successfully carried out with respect to the cell
growth phase. One batch cultivation was performed for use as a
reference. The success rate was higher for the ATF system com-
pared to the TFF system due to simpler handling (e.g. a single con-
nection for the recirculation and self-tuning of the controller).
Growth of AGE1.CR.pIX cells in four representative perfusion runs
and the batch control is shown in Fig. 3. Similar cell growth was
obtained with the two perfusion systems and high cell concentra-
tions were achieved with viabilities usually above 90–95%. An
average cell-specific growth rate (m) of 0.020 ± 0.004 h1
(mean ± SD) was achieved in the perfusion cultivations (n = 7) con-
sidering the complete cell growth phase (from inoculation until
infection). This corresponds to a doubling time (tD) of 32 ± 7 h.
The results are in agreement with previous data from perfusion
cultivations in STR using AGE1.CR [23] and AGE1.CR.pIX cells
[18]. For the perfusion cultivations with the best cell growth per-
formance (e.g., ATF #2 with tD = 27 h), viable cell concentrations
above 40  106 cells/mL were achieved 6 days after inoculation
and a maximum of 50  106 cells/mL one day after infection. In
other cultivations, the doubling time increased considerably (up
to 60%) after the start of the perfusion mode compared to the initial
batch phase (e.g. ATF #1), although cultivation conditions were
controlled and metabolite concentrations were maintained in the
desired range. These cultures were then infected at a lower viable
cell concentration to minimize medium consumption.
The concentration of extracellular metabolites of one represen-
tative perfusion cultivation and the perfusion rate used are shown
in Fig. 4. During the cell growth phase, glucose levels were usually
maintained above 10 mM after perfusion was started. Neither a
limitation of glucose nor glutamine was observed and accumula-
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Fig. 4. Metabolite concentrations of AGE1.CR.pIX perfusion cultivation ATF #2 in CD-U3 medium carried out in the SB10-X bioreactor, subsequently infected with IAV. (A)
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B
Fig. 3. Cell growth of AGE1.CR.pIX cells in CD-U3 medium in the SB10-X bioreactor (5 L initial wv) connected with ATF or TFF perfusion devices. Viable cell concentration (A)
and viability (B) of one run in batch mode ( ) and four runs in perfusion mode: ATF #1 (s), ATF #2 (d), TFF #1 (h) and TFF #2 (j) (time of infection t = 0 d).
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duction phase, ammonium concentrations increased as a conse-
quence of cell death and release of intracellular metabolites.
Nevertheless, ammonium maximum values after infection were
usually 2 mM. For cell-culture based virus production, ammonium
concentration in the culture can be critical. Early studies showed
that high concentrations of ammonium can delay or inhibit IAV
replication [30]. Furthermore, cell growth reduction after addition
of ammonium salts was reported for different cell lines, while
levels of toxicity varied greatly between studies (1–12 mM ammo-
nium concentration) [31]. In the present study, the perfusion rate
was increased in steps until 2–3 wv/d, to maintain the CSPR previ-
ously established for this cell line [18]. Our results confirmed that
the selected strategy was sufficient to supply glucose and glu-
tamine, while maintaining low levels of toxic by-products.
Oxygen supply can occasionally be a concern for operation at
high cell concentrations [32,33]. In the present work, up to
50  106 cells/mL were cultivated in the bioreactor with DO values
above 80% using a mixture of air and O2 with aeration of maximum
500 mL/min (limit: 2000 mL/min). Aeration with pure oxygen,increasing volumetric rates of aeration or increasing the shaking
frequency would potentially allow for cell growth to even higher
concentrations. Overall, we estimated a theoretical maximum cell
concentration of about 2.2  108 cells/mL based on Eq. (4) [34],
when the volumetric mass transfer coefficient (kLa), the solubility
of oxygen at saturation (C*), the oxygen concentration in the liquid
(CL) and the cellular oxygen uptake rate (qO2) are considered.
Xv ¼ kLaðC  CLÞ=qO2 ð4Þ
For the SB10-X bioreactor, the kLa was determined for aeration
with air at 1000 mL/min and shaking frequencies from 80 to
140 rpm, resulting in values of 5–25 h1 for filling volumes of
8–12 L [35]. The values used for our calculations were:
kLa = 15 h1 (corresponding to approximately 100–120 rpm),
qO2 = 3.05  1014 mol/cell/h [23], C* = 0.60 mmol/L for aeration
with 60% of O2 in the output flow (maximum value used in our
cultivations) and CL = 0.16 mmol/L for 80% of air saturation. As cal-
culated, very high concentrations of AGE1.CR.pIX cells can theoret-
ically be reached in an OSB with surface aeration only and without
using pure oxygen. Previous cultivations of AGE1.CR cells in CD-U3
7016 J. Coronel et al. / Vaccine 37 (2019) 7011–7018demonstrated that concentrations in the range 50–80 106 cells/mL
can be achieved [18,23]. For higher cell concentrations, as obtained
for CHO cells [16] or EB66 cells [17], process optimization would be
required, particularly towards medium composition to support
growth to very high cell concentrations while reducing the spent
medium volume. Additionally, depending on the cell line and
bioreactor scale, maximum cell concentrations achievable might
differ, since the qO2 varies in a broad range (from 1015 to 1013
mol/cell/h for animal cell lines) [20] and kLa values tend to be
lower at larger scales. Optimization studies to select key parame-
ters such as stirring frequency and aeration strategy could be per-
formed and process control could be improved.
3.3. Production of influenza A virus in high cell concentration
cultivations
After infection with IAV at low MOI, AGE1.CR.pIX cells typically
continued to grow for a short time (until approximately 1 day post
infection, dpi) followed by a rapid decrease in viable cell concen-
tration and viability, as demonstrated previously (Fig. 3-A). Perfu-
sion rates during the virus production phase were kept higher than
2 wv/day (up to 1 dpi) and were subsequently reduced (Fig. 4-A) to
follow the viable cell concentration profile. It is noteworthy that
the decrease in cell concentration observed over the course of
infection resulted from both the cell death and the bioreactor dilu-
tion step during the virus production phase. Volumes of 7–8 L at
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Fig. 5. Production of human influenza A virus using AGE1.CR.pIX cells grown in the SB10-
#1 (h) and TFF #2 (j) with one dilution step for virus production phase (see Table 1). (A)
cytometry data for TFF #1 (h) and #2 (j): NP positive cells, infected with influenza virus
based on DAPI signal and brightfield images.well as 10 L at low cell concentration in batch mode. In the TFF
#1 cultivation, the bioreactor volume unintentionally increased
to 9 L (1 dpi), as the membrane was partially blocked probably
due to the amount of cellular debris accumulated over the course
of infection. Nonetheless, the perfusion could be carried out at
9 L until the end of the infection phase.
Influenza A virus production dynamics are shown in Fig. 5-A
and Fig. 5-B. The highest HA titer was 3.73 log10(HA units/100 mL),
corresponding to 10.7  1010 virions/mL and the highest TCID50
titer was 8.8  109 infectious virions/mL.
Regarding process control, DO in the bioreactor was maintained
at high levels (>80%) until time of infection. Due to the oxygen
enrichment for virus production phase, a subsequent increase
(>100%) was observed, as discussed in Section 3.1. Consequently,
pH levels usually increased after infection (Fig. 5-C), as no CO2
was added in the virus production phase.
The virus concentration calculated from HA values (see Eq. (1))
was higher in OSB (Table 2) compared to previous cultivations of
AGE1.CR cells in STR (1.32–6.04  1010 virions/mL), while infec-
tious virus titers were lower than in STR (42–178  108 infec-
tious virions/mL) [23]. In case live vaccine production is
intended, further experiments are necessary to better understand
IAV replication dynamics and peak infectivity in OSB. Considering
that IAV vaccines are mainly inactivated vaccines, as exemplified
by the cell-based vaccines approved by the FDA [36], the CSVY and
the Pv were calculated based on HA (total number of virions/mL).





0 1 2 3



















Time post infection (d)
D
X bioreactor in batch mode ( ) and in perfusion mode: ATF #1 (s), ATF #2 (d), TFF
HA titer; (B) TCID50 titer; (C) pH values (offline) of perfusion runs; (D) Imaging flow
(continuous line) and apoptotic cells (dashed line), showing nuclear fragmentation,
Table 2
Overview of cell growth parameters and virus yields from AGE1.CR.pIX cells in OSB (wv 5–10 L).
Run tDa Xv, viab.b Max. cellsc Max. Cvird Max. TCID50e CSVYf Pvg
[h] [cell/mL; %] [1011] [1010 v/mL] [108 inf.v/mL] [v/cell] [1012 v/L/d]
Batch 28 12  106, 96 0.68 0.9 5.5 1286 1.4
ATF #1 43 19  106, 88 1.43 3.8 7.5 1333 n.a.*
ATF #2 26 43  106, 96 2.46 10.7 88 3059 2.0
TFF #1 27 38  106, 95 2.25 8.7 13 3487 2.2
TFF #2 41 25  106, 93 2.39 3.3 13 1055 0.48
a Doubling time (tD) during cell growth phase.
b Viable cell concentration (Xv) and cell viability (viab.) at time of infection.
c Maximum cell number after infection.
d Maximum virus concentration (Cvir) based on maximum HA titer.
e Maximum TCID50 titer.
f Cell-specific virus yield (CSVY).
g Culture medium productivity (Pv).
* Medium consumption was not monitored in ATF #1.
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these results were achieved in the runs infected at higher cell con-
centrations with short doubling time before infection (ATF #2 and
TFF #1) indicating that the better the cells grow the more virions
are produced.
Furthermore, the results suggest that virus production can be
improved in perfusion OSB, compared to batch OSB and to perfu-
sion cultivations in STR with ATF [23], which yielded CSVY of
512–1708 virions/mL. The differences observed in the two bioreac-
tor systems might be related to the response of cells to shear stress
(lower in OSB) and also to the infection conditions. Particularly, the
dilution step used in the present study for the virus production
phase was shown to enhance virus production [18]. Further exper-
iments are necessary to better understand how the choice of the
bioreactor system impacts cell growth and consequently virus pro-
duction and how the cultivation conditions can be further opti-
mized during the virus production phase. For instance, perfusion
studies for adenovirus production investigated the effect of feeding
rates (0.5–3 wv/d) and the highest titer was obtained with 2 wv/d
[37]. Another optimization can be towards the selection of the
retention device. Currently, the preferred perfusion devices are
membrane-based (ATF and TFF) because high virus titers
[17,18,23] and very high cell concentrations were reported using
these systems [16] and both can be used at large scale under cGMP
conditions [2]. However, undesired product retention has been
reported for recombinant proteins [33,38] and viruses [17,18,23].
Retention of IAV was observed using hollow fiber membranes of
different materials (PS or PES) and pore sizes (50 kDa, 500 kDa,
0.2 mm and 0.5 mm) [17,18,23]. Negative effects on virus production
were not observed for the larger cut-offs [23], while lower virus
titers and lower cell-specific virus yield were however obtained
with the 50 kDa membrane [23]. In the present work, cut-offs of
500 kDa (PS) and 0.2 mm (PES) were used and similar results were
obtained. Better yields could be potentially obtained using perfu-
sion devices that enable continuous virus harvesting, thus prevent-
ing virus degradation [39]. In addition, a disposable perfusion
system would be desirable for connecting with single-use
bioreactor.
Finally, to monitor the IAV replication dynamics at low MOI
infection, samples from two perfusion runs (TFF #1 and TFF #2)
were analyzed using imaging flow cytometry (Fig. 5-D). Almost
the complete cell population (above 95%) was infected between
24 and 36 hpi indicating that the infection procedure was success-
fully carried out. The time point of maximum percentage of
infected cells is correlated with the maximum HA values
(Fig. 5-A), before the onset of cell death. Virus-induced apoptosis
is a complex process [40] with different proteins modulating thecourse of infection and impacting the final virus titers [41,42]. In
the cell-based IAV production system investigated, virus titers in
the bioreactor decreased (Fig. 5-A) with an increase in the percent-
age of apoptotic cells (Fig. 5-D). Similar replication dynamics were
observed in cultivations with adherent MCDK cells, although virus
replication and release started earlier due to the high MOI used
[29]. In addition, it has been reported that adherent MDCK cells
cease virus release and detach from their substrate after onset of
apoptosis in microcarrier cultivations [43].4. Conclusion
For the first time, a cell-based IAV production process in an OSB
coupled to perfusion devices is described. Growth of suspension
AGE1.CR.pIX cells in chemically defined medium to high cell con-
centrations in perfusion mode (50  106 cells/mL) was demon-
strated. High cell viabilities and short doubling times could be
obtained in both TFF and ATF cultivations. Based on the cellular
oxygen consumption rate of AGE1.CR.pIX cells and the oxygen
transfer rate of SB10-X, cell concentrations up to 2.2 108 cells/mL
should be feasible. Cultivations were successfully performed at
7–8 L scale in perfusion mode and at 10 L scale in batch mode, dur-
ing virus production. IAV production was improved in the best per-
fusion cultivations compared to batch mode concerning HA titer,
TCID50 titer, CSVY and Pv. Using the OSB, the highest values
reported so far for AGE1.CR.pIX cells regarding CSVY (up to
3500 virions/cell) and Pv (up to 2.2  1012 virions/L/d) were
obtained. On the other hand, infectious virus titers obtained in
OSB were lower compared to previous perfusion experiments per-
formed in STR indicating options to further process optimization.
As addressed previously, the choice of the bioreactor system is
important for scale-up, especially in the case of shear sensitive
cells such as AGE1.CR.pIX. Orbital shaken technology was suitable
for cultivating these cells, suggesting that other animal cell lines
could also be successfully cultivated in OSB in perfusion mode.
Due to a simpler bag design (no stirrer, no coupling) we believe
that the OSB technology could be a very competitive alternative
to an STR. Furthermore, since both OSB and ATF systems are scal-
able, IAV production in perfusion mode could potentially be trans-
ferred from laboratory scale to production scale.
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